Astrazeneca (AZN) Raw Materials (2016 - 2025)

Astrazeneca has reported Raw Materials over the past 11 years, most recently at $1.9 billion for Q4 2025.

For Q4 2025, Raw Materials rose 24.71% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 24.71%, while the annual FY2025 figure was $1.9 billion, 24.71% up from the prior year.
Raw Materials for Q4 2025 was $1.9 billion at Astrazeneca, up from $1.5 billion in the prior quarter.
Over five years, Raw Materials peaked at $1.9 billion in Q4 2025 and troughed at $1.4 billion in Q4 2022.
A 5-year average of $1.6 billion and a median of $1.5 billion in 2023 define the central range for Raw Materials.
Biggest five-year swings in Raw Materials: soared 39.06% in 2021 and later fell 18.97% in 2022.
Year by year, Raw Materials stood at $1.8 billion in 2021, then fell by 18.97% to $1.4 billion in 2022, then increased by 7.67% to $1.5 billion in 2023, then fell by 2.74% to $1.5 billion in 2024, then grew by 24.71% to $1.9 billion in 2025.
Business Quant data shows Raw Materials for AZN at $1.9 billion in Q4 2025, $1.5 billion in Q4 2024, and $1.5 billion in Q4 2023.

Peer Comparison